| K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer CS Karapetis, S Khambata-Ford, DJ Jonker, CJ O'Callaghan, D Tu, ... New England Journal of Medicine 359 (17), 1757-1765, 2008 | 4473 | 2008 |
| Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Yokoi, ... New England Journal of Medicine 377 (20), 1919-1929, 2017 | 4000 | 2017 |
| Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ... New England Journal of Medicine 379 (24), 2342-2350, 2018 | 2599 | 2018 |
| Cetuximab for the treatment of colorectal cancer DJ Jonker, CJ O'Callaghan, CS Karapetis, JR Zalcberg, D Tu, HJ Au, ... New England Journal of Medicine 357 (20), 2040-2048, 2007 | 2427 | 2007 |
| Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ... The Lancet 392 (10142), 123-133, 2018 | 1135 | 2018 |
| Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab W De Roock, DJ Jonker, F Di Nicolantonio, A Sartore-Bianchi, D Tu, ... Jama 304 (16), 1812-1820, 2010 | 877 | 2010 |
| Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer J Tie, I Kinde, Y Wang, HL Wong, J Roebert, M Christie, M Tacey, R Wong, ... Annals of Oncology 26 (8), 1715-1722, 2015 | 630 | 2015 |
| Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials MJ Sorich, MD Wiese, A Rowland, G Kichenadasse, RA McKinnon, ... Annals of Oncology 26 (1), 13-21, 2015 | 603 | 2015 |
| Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study JW Valle, D Palmer, R Jackson, T Cox, JP Neoptolemos, P Ghaneh, ... Journal of clinical oncology 32 (6), 504-512, 2014 | 446 | 2014 |
| Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials A Drilon, S Siena, R Dziadziuszko, F Barlesi, MG Krebs, AT Shaw, ... The Lancet Oncology 21 (2), 261-270, 2020 | 410 | 2020 |
| Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO. 17 SY Brulé, DJ Jonker, CS Karapetis, CJ O’Callaghan, MJ Moore, R Wong, ... European journal of cancer 51 (11), 1405-1414, 2015 | 384 | 2015 |
| Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer A Rowland, MM Dias, MD Wiese, G Kichenadasse, RA McKinnon, ... British journal of cancer 112 (12), 1888-1894, 2015 | 375 | 2015 |
| First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE … HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ... The Lancet Oncology 18 (9), 1159-1171, 2017 | 369 | 2017 |
| Colorectal cancer: Metastases to a single organ S Vatandoust, TJ Price, CS Karapetis World journal of gastroenterology 21 (41), 11767, 2015 | 351 | 2015 |
| Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer D Yip, C Karapetis, A Strickland, CB Steer, D Goldstein Cochrane database of systematic reviews, 2006 | 285 | 2006 |
| Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study J Tie, JD Cohen, Y Wang, L Li, M Christie, K Simons, H Elsaleh, ... Gut 68 (4), 663-671, 2019 | 281 | 2019 |
| Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study … HJ Schmoll, D Cunningham, A Sobrero, CS Karapetis, P Rougier, ... Journal of clinical oncology 30 (29), 3588-3595, 2012 | 219 | 2012 |
| PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17 CS Karapetis, D Jonker, M Daneshmand, JE Hanson, CJ O'Callaghan, ... Clinical Cancer Research 20 (3), 744-753, 2014 | 190 | 2014 |
| Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving … GS Patel, K Jain, R Kumar, AH Strickland, L Pellegrini, J Slavotinek, ... Supportive care in cancer 22, 121-128, 2014 | 178 | 2014 |
| High rate of complications associated with peripherally inserted central venous catheters in patients with solid tumours K Cheong, D Perry, C Karapetis, B Koczwara Internal medicine journal 34 (5), 234-238, 2004 | 174 | 2004 |
Timothy PriceThe Queen Elizabeth Hospital and School of Medicine University of AdelaideVerified email at adelaide.edu.au
